Podcasts about wet amd

Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]

Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]

Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]

Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]

Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]

Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]

Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]

Tens of thousands of real-world geographic atrophy patients were analyzed in a retrospective database study. How did GA progress—and how do these data inform our understanding of GA? Ted Leng, MD, stopped by the show to share the findings from his research on the natural history of GA, which he recently delivered on the podium in Lisbon. And Michael Klufas, MD, joined us for a discussion about another real-world study. This time, it was a retrospective multicenter outcomes analysis following multiple injections of high-dose aflibercept (Eylea HD, Regeneron) for treatment of wet AMD, DME, and DR. How did treatment-naïve patients fare compared with previously treated patients? And did treatment intervals improve? Stick with us to find out.

Known as 4D-150, the wet AMD gene therapy performed well in a Phase 2b clinical trial.

Does switching long-term wet AMD patients to faricimab (Vabysmo, Genentech/Roche) result in meaningful change to disease presentation? Join New Retina Radio Journal Club host Ben Young, MD, MS, and panelists Lediana Goduni, MD, and Josh Uhr, MD, as they break down a recent real-world study published in the literature. After the break, they review whether the study's findings could inform clinical decision-making, weigh the value of anatomic improvement that doesn't result in significant improvement in vision quality, and review their comfort with switching from legacy anti-VEGF agents to next-generation therapies.

New steroid-free topical for atopic dermatitis; A refillable ocular implant for the treatment of  neovascular (wet) age-related macular degeneration returns following recall; A neuroimmune modulation device shows clinical benefit in adults with rheumatoid arthritis; FDA denies Novo Nordisk's once-weekly insulin icodec; And a smarthphone therapy shows benefit for patients with fibromyalgia.

FDA-approved in 2021, the tiny implantable capsule provides sustained delivery of treatment, but was recalled in 2022.

Alice Findlay, RNIB Customer Voice Insight Co-ordinator shares the latest opportunities for blind and partially sighted people to get involved in with RNIB Connect Radio's Toby Davey. Opportunities highlighted this week included: Parenting with a Vision Impairment In-Person Discussion Join us for an in-person discussion on parenting with a vision impairment, hosted by RNIB's Stories and CYPF teams as part of Spotlight on Stories week. The event takes place on 20 June from 11am-1.30pm at RNIB's London office - the Grimaldi building, 154a Pentonville Road, London, N1 9JE on the third-floor mezzanine. CYPF Family Support Officer and former ECLO Jenny Molineux will share her experiences as a visually impaired mum and introduce the CYPF Parenting with Vision Impairment guide. She will be joined by other mothers with vision impairments to discuss their challenges, followed by a Q&A session. Sensitive topics will be covered. There's limited capacity for the event, so please RSVP to stories.library@rnib.org.uk by Friday 14 June if you'd like to attend.  Do you have Geographic Atrophy (GA) or care for someone who does?  Take part in a study and earn £65! Geographic Atrophy (also known as GA) is most often seen in people who live with Wet AMD, Dry AMD, Glaucoma and Cataracts. Exafield UK (a medical market research company) are carrying out research on behalf of a pharmaceutical company. The aim of their research is to understand your journey with GA. By collecting these experiences, they hope to build a better picture of eyesight degeneration and understand what could be improved to better manage this condition. The study will consist of a 30-minute pre-task homework completed online and a 75-minute online interview. As a thank you for your time, you will receive £65, which is payable as a bank transfer, Cheque or Amazon Voucher. If you're interested in taking part in the study, please send an email to involvement@rnib.org.uk and we will send you the link to apply to take part in the study.  Are you living with sight loss and are interested in sharing your experiences of relationships and sexual well-being?  SASH, a mental health and wellbeing charity focused on sexual health who offer a range of services including counselling, coaching, peer support, training, and workshops. They are looking for people who would be willing to be interviewed and recorded as part of their podcast series on sexual health. If this interests you, they would love to interview you to help raise awareness, discuss barriers you experience, and address misconceptions around relationships for those navigating life with sight loss.  Complimentary drinks, snacks and a £50 Amazon voucher will be provided as a thank you for sharing your lived experience with SASH. To get involved contact Sade Vassel either by phone on 07928 512 465 or email sade.vassel@turning-point.co.uk. To find out more about these and other Connect Voices opportunities along with how you can get involved with RNIB Connect Voices do visit- https://www.rnib.org.uk/connect-community/connect-voices-network/connect-voices-current-opportunities (Image shows RNIB logo. 'RNIB' written in black capital letters over a white background and underlined with a bold pink line, with the words 'See differently' underneath)

Dr. Sarraf talks about his group's work on the correlation of PED size and variablity and the visual improvement during the treatment of neovascular AMD as analyzed using data from HAWK and HARRIER studies. Referenced article:  Sarraf D, Khanani AM, Sadda SR, Chang A, Wong DT, Kempf AS, Saffar I, Tang S, Tadayoni R. PIGMENT EPITHELIAL DETACHMENT THICKNESS AND VARIABILITY AFFECTS VISUAL OUTCOMES IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2024 Jan 1;44(1):10-19. doi: 10.1097/IAE.0000000000003935. PMID: 37824807.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPZ865. CME credit will be available until December 21, 2024.Optimizing Real-World Outcomes in Wet AMD: Reducing the Burden of Treatment With Longer-Acting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRishi P. Singh, MD, FASRS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alcon; Apellis Pharmaceuticals; Bausch & Lomb Incorporated; Genentech, Inc.; IVERIC bio, Inc., An Astellas Company; Novartis/Gyroscope; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPZ865. CME credit will be available until December 21, 2024.Optimizing Real-World Outcomes in Wet AMD: Reducing the Burden of Treatment With Longer-Acting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRishi P. Singh, MD, FASRS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alcon; Apellis Pharmaceuticals; Bausch & Lomb Incorporated; Genentech, Inc.; IVERIC bio, Inc., An Astellas Company; Novartis/Gyroscope; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

What are the consequences to intentional suspension of anti-VEGF therapy in wet AMD patients? Join moderator Sruthi Arepalli, MD, and panelists Rebecca Soares, MD, MPH, and Vaidehi Dedania, MD, as they explore the circumstances under which treatment might be suspended, examine a paper that described the consequences of treatment suspension, and review how they approach treatment suspension in their clinics.

They're here: the 96-week data on aflibercept 8 mg (Eylea, Regeneron) in wet AMD. Jean-Francois Korobelnik, MD, PhD stops by to review the 96-week data from PULSAR. How closely did the 96-week results match those at 48 weeks? And how many patients could be extended to 16-, 20-, or even 24-week intervals?    Also, W. Lloyd Clark, MD, joins the show to discuss home-based OCT-guided management of wet AMD. How does home OCT fit into a patient's life—and how might it shape the future of care? Listen here to find out. 

Guest speaker W. Lloyd Clark, MD, discusses a new anti-VEGF treatment option that is available for wet AMD. Dr. Clark specializes in the treatment of vitreous and retinal diseases. He is also dedicated to the advancement of new treatments for retinal diseases through his involvement with clinical trials for the newest therapies for age-related macular degeneration, diabetic retinopathy, and retinal vein occlusions.

Drs. Katherine Talcott and Joshua Uhr preview the September 2023 issue of Retinal Physician, found online at http://www.retinalphysician.com. Topics covered include high-dose aflibercept FDA approval, management of treatment-resistant wet AMD patients, biosimilar intravitreal injections, and lifestyle factors and AMDRelevant Financial Disclosures: Dr. Sridhar is a consultant for Genentech and Regeneron. Dr. Talcott is a consultant for Genentech.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

In this episode, Ayesha talked about how three more US states have filed a lawsuit against Eli Lilly over its proposed $13.5 million insulin pricing settlement. The states join six others who have been fighting Eli Lilly in court since 2017, claiming that the company hiked prices of its insulin product Humalog. The states say the $13.5 million settlement offer from Eli Lilly doesn't come close to the $1 billion worth of claims the company is facing. Hear more about the insulin pricing controversy in this episode.Ayesha also talked about the FDA approval of Regeneron's high dose Eylea (HD Eylea) for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). Hear about how high dose Eylea offers less frequent dosing regiments, and how it will be facing Roche's blockbuster eye injection Vabysmo.Read the full articles here:More US States Take on Eli Lilly in Court Over Proposed $13.5 Million Insulin Pricing SettlementRegeneron's High Dose Eylea Gets FDA Nod for Wet AMD and DMEFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

New Retina Radio was at ASRS 2023 to cover the stories you may have missed.    How often do patients return to the clinic on time for anti-VEGF injections? Christina Y. Weng, MD, MBA, and her team explored how often patients missed scheduled appointments, by how much, and whether missing appointments affected patient outcomes.    And Nikolas JS London, MD, joined us in our mobile studio in Seattle to tell us about anatomic outcomes in wet AMD patients after faricimab (Vabysmo, Genentech/Roche) treatment.    This is episode 1 of 2 covering the 2023 ASRS Annual Meeting. Keep an eye on your feed for episode 2.  

Were fluid-free visits correlated with outcomes in the HAWK/HARRIER studies? Moderator Katherine Talcott, MD, and panelists Kyle Kovacs, MD, and Rebecca Soares, MD, MPH, summarize data from a study examining this question, review what it means to be "free of fluid," and discuss how these data fit into the overall conversation about fluid toleration in wet AMD. 

How are doctors using faricimab (Vabysmo, Genentech/Roche) in real-world settings? The IRIS Registry has a few answers. We sat down with Durga Borkar, MD, MMCi, to hear what researchers in the FARETINA-AMD study group found regarding dynamics related to faricimab's use in wet AMD patients since its approval in January of last year.    We also interviewed Varun Chaudhary, MD, to learn specifically about faricimab treat-and-extend regimens in wet AMD patients who were enrolled in TENAYA and LUCERNE. How many patients achieved treatment intervals of 12 or 16 weeks? 

This event featured Dr. Surendra Sharma, Senior VP of Medical Affairs at Outlook Therapeutics. Dr. Sharma discussed the difference between Wet AMD and Dry AMD, who is at risk for Wet AMD, and what treatment options are available.

Dr. Jay Duker speaks about the results of the DAVIO trial which was a phase 1 trial investigating an intravitreal implant (EYP-1901) containg vorolanib (a VEGF and receptor blocker) in a bioerodible Durasert implant for the treatment of wet AMD. 

Millions of people in the United States live with eye conditions that can cause blindness if left untreated. One of the most common causes of vision loss later in life is age-related macular degeneration and wet AMD, an advanced form that can cause severe and rapid vision loss, but it can be stopped or slowed if caught early enough. Dr. Talia Kaden, is an ophthalmologist at Manhattan Eye, Ear and Throat Hospital joins me ways to help you prioritize your eye health and about treatments for wet AMD.

Millions of people in the United States live with eye conditions that can cause blindness if left untreated. One of the most common causes of vision loss later in life is age-related macular degeneration and wet AMD, an advanced form that can cause severe and rapid vision loss, but it can be stopped or slowed if caught early enough. Dr. Talia Kaden, is an ophthalmologist at Manhattan Eye, Ear and Throat Hospital joins me ways to help you prioritize your eye health and about treatments for wet AMD.This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/3501571/advertisement

Outlook Therapeutics Inc (NASDAQ:OTLK) President and CEO Russ Trenary tells Proactive's Stephen Gunnion that the company faces the most significant milestone in its history if the US Food and Drug Administration (FDA) approves its investigational ophthalmic formulation for treating wet age-related macular degeneration (wet AMD). The FDA has already accepted Outlook's Biologics License Application, with a Prescription Drug User Fee Act goal date of 29 August 2023. If approved, Trenary says ONS-5010 – brand name Lytenava – is expected to receive 12 years of regulatory exclusivity in the US. It will hit the ground running due to a recent strategic relationship it entered with AmerisourceBergen, he adds. #ProactiveInvestors #OutlookTherapeutics #wetAMD #FDA #AmerisourceBergen #Nasdaq

Max Conway, RNIB's National Involvement Coordinator, shares the latest opportunities for blind and partially sighted people to get involved in. Opportunities highlighted this week included: Call out for would-be blind or partially sighted movie stars to be part of a short film about Wet-AMD. Fixing US, a health engagement organisation focusing on patient journeys across all kinds of health conditions are looking for people living with Wet-AMD who would be willing to participate in a short film about their condition. Do you play a musical instrument and would like to break down the barriers blind and partially sighted musicians face? Rachel, a PhD student at the University of Plymouth, is looking to gather information from blind and partially sighted musicians to help aid the development of an accessible digital musical interface that will enable visually impaired musicians to play in an ensemble setting alongside sighted musicians.   To find out more about these items and how you can get involved with RNIB Connect Voices do visit - https://www.rnib.org.uk/connect-community/connect-voices-network/connect-voices-current-opportunities (Image shows RNIB logo. 'RNIB' written in black capital letters over a white background and underlined with a bold pink line, with the words 'See differently' underneath) 

Drs. Marcus and Singer explore the topic individualizing the treatment approach in Wet AMD including treat and extend, monthly or maximum tolerated interval. Dr. Singer goes into depth on his approach to “treat and extend” including certain caveats and circumstances that could change how long he would extend a patient as well as the importance of balancing convenience, adherence, and efficacy.

BrightFocus Foundation held this Access Live Event to speak with participants about eye care. Our guest speaker was Alicia Menezes, M.D., a Medical Director in U.S. Medical Affairs, Ophthalmology at Genentech. Topics of discussion included comprehensive exams, treatments, and new advances in research.

Charlotte Jones, RNIB's National Involvement Coordinator shares the latest opportunities for blind and partially sighted people to get involved in. Opportunities highlighted this week included: Did you have a power cut for 2 or more days because of a winter storm? A team from Kings College London are looking for people with a disability or health  condition who experienced power cuts for 2 days or more during the 2021–22 winter season to share their experiences with researchers in a video or telephone call to find out what support people need in future power cuts. Join a virtual forum and share your experiences of Wet-AMD to help raise awareness! Fixing Dad, a health engagement organisation who look into patient journeys across all kinds of health conditions are looking for people living with wet-AMD who would be willing to participate in a one-hour online discussion to share their experiences about what it's like for them to live with Wet-AMD. The RNIB website is being redeveloped and we need your help! Our website rnib.org.uk is in the process of being updated and redeveloped and we need your help with user testing. Earlier this year we held interviews with different types of users to understand their experiences of our website and now, we're asking for help to test the prototypes of our new website. We are keen to hear from the friends and family of blind and partially sighted people and also people who have been recently diagnosed with sight loss.  To find out more about these items and how you can get involved with RNIB Connect Voices do visit - https://www.rnib.org.uk/connect-community/connect-voices-network/connect-voices-current-opportunities (Image shows RNIB logo. 'RNIB' written in black capital letters over a white background and underlined with a bold pink line, with the words 'See differently' underneath) 

Drs. Shriji Patel, Safa Rahmani, and Marianeli Rodriguez join to discuss the April 2022 edition of Retinal Physician, found online at http://www.retinalphysician.com. Topics covered include photobiomodulation for retinal disease, strategies for dry and wet macular degeneration, and more.Relevant Financial Disclosures: Dr. Sridhar is a consultant for Genentech and Regeneron. Drs. Patel, Rahmani, and Rodriguez have no relevant disclosures. You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Outlook Therapeutics Inc CEO Russ Trenary tells Proactive it has submitted its Biologics License Application to the FDA for ONS-5010, an investigational therapy for the treatment of wet age-related macular degeneration (wet AMD). If approved, the treatment will be branded as LYTENAVA (bevacizumab-vikg) and could replace the current practice of using unapproved repackaged IV bevacizumab sourced from compounding pharmacies, products that have known risks of contamination and inconsistent potency and availability.

Have innovations in therapy actually led to a paradigm shift when it comes to encountering patients with newly diagnosed wet AMD? In the season finale of “The Art of Drug Choice,” moderator Arshad M. Khanani, MD, MA, is joined by panelists Lejla Vajzovic, MD, and Joseph M. Coney, MD, to review strategies for treating new wet AMD patients, to discuss where new technologies fit into a treatment algorithm, and to examine the best time to switch patients to a new therapeutic option. After the break, Dr. Khanani updates the panel on a patient case shared in previous seasons of this series, which involves a patient with a 12-year treatment history who experienced significant vision loss following a change in therapy. How did Dr. Khanani manage the case—and what happened after inflammation was brought under control?   This editorially independent podcast is supported with advertising.

Kodiac Sciences is developing KSI-301 for a number of proliferative endothelial retinal disorders. Their recent P3 wet AMD data readout failed to show non-inferiority to Q8W dosed Eylea, a major upset for the company. However, KOD has a number of other upcoming P3 trial readouts that will be massive movers for the stock. In this episode, I go over the P3 data and talk about whether or not this is a buying opportunity. I also talk about Karyopharm and their recent regulatory update about the SIENDO data. Thanks to InfoPathways for being a sponsor of the show! Check them out for all your biotech IT needs at infopathways.com or call 410-751-9929. Help out the show (or join the discord) by becoming a patron at: https://www.patreon.com/breakingbiotech Follow me on twitter @matthewlepoire Send me an email matthewlepoire@gmail.com www.breakingbiotech.com #breakingbiotech Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt (nor his guests) cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt (nor his guests) is/are not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt (nor his guests) does/do not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech

How have the most recent advances in wet AMD therapy changed the treatment landscape for clinicians? In this debut episode of the third season of “The Art of Drug Choice,” moderator Arshad M. Khanani, MD, MA, is joined by Lejla Vajzovic, MD, and Joseph M. Coney, MD, for a discussion about choosing patients who are best suited for the recently approved therapies, and for a preview of how biosimilars could affect treatment decisions. After the break, Dr. Coney shares the case of a patient whose need to extend treatment intervals was addressed by switching to a new anti-VEGF agent. This editorially independent podcast is supported with advertising.

In the culmination of this case-based series discussing who is best suited for which types of wet AMD therapy, John Kitchens, MD, invites Murtaza Adam, MD, and Aleksandra Rachitskaya, MD, to the program to showcase two real-world patient files. After they are done with case discussions, Drs. Adam, Kitchens, and Rachitskaya examine how patient lifestyle details may affect treatment strategies.  This editorially independent podcast is supported with advertising.

In the second installment of this ongoing series covering wet AMD, Lisa Faia, MD, and Sumit Sharma, MD, submit to host John Kitchens, MD, a set of real-world patient cases in which treatment challenges necessitated a change in therapy. After revealing which treatment option is best suited for their respective patients, Drs. Faia and Sharma parse which patient types are eligible for long-duration treatment and which types are better matched for more traditional approaches. 

 In the first of this three-part series reviewing topics in wet AMD, Carl Regillo, MD, and Adrienne Scott, MD, join moderator John Kitchens, MD, to submit a pair of real-world patient cases illustrating how the need to reduce the burden of care may drive treatment decisions in patients with wet AMD. After they reveal how they managed their respective patient cases, Drs. Regillo and Scott join Dr. Kitchens for a review of how the latest innovations in retina could improve patients' lives by alleviating treatment burden.

The biosimilars are coming—and studies about them are starting to fill the literature. One such study is the COLUMBUS-AMD study, which evaluated the clinical equivalence of FYB201 to ranibizumab for the treatment of wet AMD. Aleksandra Rachitskaya, MD, breaks down the study with Emmanuel Chang, MD, PhD; Michael Klufas, MD; and Dmitra Skondra, MD. The group expands on what biosimilars are and asks what the future of retina could look like if biosimilars are approved for clinical use. 

Can anti-VEGF agents act as effective prophylactic treatment for diabetic patients with a high risk of developing diabetic eye disease? Data from the Protocol W's 2-year timepoint shared at the 2021 AAO Annual meeting might provide some answers on that question. Raj Maturi, MD, joined New Retina Radio to discuss his podium presentation on the topic.  New Retina Radio also invited Usha Chakravarthy, MD, PhD, to the program to outline her presentation on the secondary endpoints of the EDNA study. What was found when a team closely monitored patients for progression of unilateral to bilateral wet AMD? Join us on this episode to hear the details from these two presentations. 

Peter Kaiser, MD and Carol Regillo, MD, FACS discuss the port delivery system and how it impacts treatment of wet AMD.

The pipeline in retina is bursting! Which datasets shared at the ASRS 2021 meeting provided insights into the future of retina? Mark Barakat, MD, joins the podcast to discuss topline results from a study examining the suprachoroidal delivery of RGX-314 (RegenxBio). And Nancy Holekamp, MD, stops by to educate us on the potential for targeting C1q in the complement cascade in patients with geographic atrophy. What's the latest with the phase 2 ARCHER study? Find out on this episode.

In this episode, Ayesha discusses the FDA's authorization of Pfizer/BioNTech's COVID-19 vaccine for children between five and 11 years of age. The authorization was based on trial data that showed the vaccine was safe, well-tolerated and induced robust immune responses among children in this age group; side effects were generally mild to moderate. Amid concerns of the rare adverse event of myocarditis in children and adolescents following vaccination with mRNA vaccines, the FDA conducted its own benefit-risk analysis that showed the benefit of vaccination outweighs the risk of myocarditis. The editorial team discussed the positive trial data, the importance of vaccinating kids amid rising infections among younger children, as well as vaccine hesitancy among parents.The team also learned about the FDA approval of Genentech's new ocular implant drug delivery system, called Susvimo, for the treatment of neovascular, or wet, age-related macular degeneration (nAMD). The implant is surgically placed in the eye and injected with Genentech's anti-VEGFA monoclonal antibody ranibizumab for continuous delivery. Compared with the current standard of care of near monthly intravitreal anti-VEGF injections, the ocular implant only has to be refilled every six months. The team discussed the convenience of the device, but also potential patient hesitancy over the surgery for its implantation.Read the full articles here: FDA Authorizes Pfizer/BioNTech COVID-19 Vaccine for Kids 5 to 11 Genentech's New Ocular Implant Drug Delivery System for Macular Degeneration Could Be a Game ChangerFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured 

The US Food & Drug Administration (FDA) has approved Susvimo, Genentech's port delivery system (PDS) with ranibizumab, for the treatment of wet age-related macular degeneration (AMD). The PDS, a refillable capsule the size of a rice grain, provides continual release of ranibizumab, a protein that blocks the growth of vision-robbing, leaky blood vessels which are the hallmark of wet AMD. The PDS is implanted at the surface of the eye during a one-time, outpatient, surgical procedure. The PDS may be refilled as infrequently as twice a year. Susvimo will be available to patients in the coming months.

REGENXBIO ($RGNX) presents data using the Clearside Bio ($CLSD) SCS injector to treat wet AMD and diabetic retinopathy patients with RGX-314. Since existing treatments are on the market for these indications, it is very important that safety signals in these studies are reduced to a minimum. It is also critical that efficacy remains non-inferior to Eylea or Lucentis. In this video, I go through both readouts and discuss the potential for the therapy moving forward. 4D Molecular Therapeutics ($FDMT) announces positive early interim data in their intravitreal treatment of 4D-125 in patients with X-linked Retinitis Pigmentosa. With only a small patient population to analyze, it is difficult to derive much conclusion, but so far the efficacy and safety is hopeful. Patients advanced in their disease and also had an extensive prophylactic regimen, making it difficult to assess the treatment's success. In this video, I go through the details of the space and talk about what's next for FDMT. Help out the show (or join the discord) by becoming a patron at: https://www.patreon.com/breakingbiotech Follow me on twitter @matthewlepoire Send me an email matthewlepoire@gmail.com www.breakingbiotech.com #breakingbiotech Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech

Bridging Business and Biotechnology: Kodiak Sciences Is Increasing Treatment Efficacy for Retinal Diseases Victor Perlroth, MD, the Chairman and CEO of Kodiak Sciences, discusses how the company's ABC platform medicines are designed to treat the leading causes of blindness.   Age-related macular degeneration (AMD) is one of the leading causes of blindness in adults worldwide. This disease deteriorates the macula, a miraculous little spot on your retina that allows for precise vision in good light. Although several treatments exist for macular deterioration, they require frequent trips to the doctor's office for uncomfortable but quick and routine injections directly into the eye. The required frequency of the treatments means that most patients miss appointments, leading to undertreatment of the disease and permanent vision loss. In a manufacturing collaboration with Lonza, Kodiak is designing novel antibody-biopolymer conjugate (or ABC) medicines with the same efficacy and safety with much longer durability, allowing patients to visit the doctor on a realistic schedule over the long term. By focusing on business implementation alongside formidable biotech R&D, Kodiak Sciences is on track to bring together the necessary clinical and manufacturing elements for an FDA filing in 2023.   Curious to Know More? In this most recent episode of “A View On,” Lonza's Martina Hestericová is joined by Victor Perlroth, MD, the Chairman and CEO of Kodiak Sciences, to talk about the recent developments in AMD treatment research.    KEY TERMS:   Age-related macular degeneration (AMD) is a common degenerative disease of the retina. There are two types of AMD: Dry AMD occurs when the formation of debris (drusen) on the retina causes the macula to deteriorate over time. Patients sometimes experience vision loss and frequently experience substantial functional limitations, including vision fluctuations, loss of peripheral vision, and reduced night vision. Wet AMD is an advanced form of AMD. While wet AMD represents only 10% of the number of cases of AMD overall, it is responsible for 90% of AMD-related cases of severe vision loss. Wet AMD occurs when the growth of abnormal blood vessels underneath the macula leads to leakage of fluid and blood, which leads to visual distortion, acute vision loss, and total blindness if left untreated. Vascular endothelial growth factor (VEGF) is a sub-family of factors that stimulate the growth of blood vessels. In the case of AMD, these VEGF are overexpressed, creating leaking in the macula. This leakiness causes fluid to exit from blood vessels, causing swelling – or edema – of the retina and loss of vision. An antibody biopolymer conjugate (ABC) is Kodiak Science's proprietary platform for designing and developing drugs into the retina. The antibody in the KSI-301 molecule inhibits VEGF, while the biopolymer is comprised of phosphorylcholine, which creates a sort of “water cloak” around the antibody to increase its effectiveness. Phosphorylcholine is a natural component of the cell membrane of all the cells in our body, with remarkable properties. It attracts and binds water in a very strong – even permanent – way, creating what is known as “structured water,” which then impacts all biological interactions in the local area.

Safety will ultimately drive decision-making for patients with wet AMD. What are the latest safety data in the MERLIN, ARCHWAY, OPTIC, RGX-314, and TENAYA/LUCERNE trials? Moderator Arshad M. Khanani, MD, MA (United States), and panelists Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), sift through the latest safety data to determine how concerns about safety could shape the future of wet AMD therapy. 

The pipeline of wet AMD treatments is inspiring. What can retina specialists around the world expect when it comes to wet AMD therapy candidates KSI-301 (Kodiak Sciences), RGX-314 (RegenxBio), and ADVM-022 (Adverum Biotechnologies)? Join moderator Arshad M. Khanani, MD, MA (United States), and panelists Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), as they review early-phase data from some of the possible wet AMD drugs of the future. 

Drs. Sabin Dang, Avni Finn, and Yoshihiro Yonekawa join to discuss four recent publications in major ophthalmology journals.Gender Pay Gap (https://www.aaojournal.org/article/S0161-6420(21)00513-3/fulltext)Pneumatic Retinopexy (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2781202?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jamaophthalmol.2021.1860)Home Monitoring for Wet AMD (https://www.ophthalmologyscience.org/article/S2666-9145(21)00032-4/fulltext)Career Choices of Ophthalmology Trainees (https://www.ajo.com/article/S0002-9394(21)00333-0/fulltext)Relevant Financial Disclosures: Dr. Sridhar has consulted for Alcon, Allergan Dorc, Genentech, Regeneron, and Oxurion. Dr. Dang has consulted for Regeneron and has a paid research grant from Bausch and Lomb. Dr. Finn has consulted for Genentech and Allergan. Dr. Yonekawa has consulted for Alcon, Alimera, Allergan, and Genentech.You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

If new treatment options for wet AMD are approved for treatment, retina specialists will have even more options to switch patients to a new therapy. Which drug candidates have phase 3 data and real-world data that could point toward upcoming action by regulatory bodies? Arshad M. Khanani, MD, MA (United States), convenes an international panel comprised of Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), to review data related to brolucizumab (Beovu, Novartis), the Port Delivery System with Ranibizumab (Genentech), and faricimab (Roche). 

Nancy Lurker: President & Chief Executive Officer Our President, CEO, and a director since September 2016, Ms Lurker has broad-ranging experience in the pharmaceutical industry and a track record of maximizing the potential of new therapies and successfully implementing innovative US and global drug launches. Said Saim, PhD: Chief Technology Officer Dr Saim has more than 25 years of product development experience. Dr Saim has published 22 papers in engineering and science journals, holds 18 patents, and earned a PhD in chemical engineering from the University of Kansas.

Retina specialists around the world aim to reduce treatment burden while maximizing therapeutic outcomes in patients. How do global experts decide when to switch and to which therapy? Arshad M. Khanani, MD, MA (United States), is joined by Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), to discuss tactics for moving wet AMD patients to new therapies or regimens. Also, Prof. Garweg shares a case of a patient who benefited from a new treatment option approved for wet AMD. 

In this roundtable moderated by Allen C. Ho, MD, experts in gene therapy discuss the latest data, clinical trial hurdles, and the promise these programs hold for patients being treated for wet AMD. Participants include Robert L. Avery, MD; Peter Campochiaro, MD, PhD; Jeffrey S. Heier, MD; Szilárd Kiss, MD; and Charles Wykoff, MD, PhD.

Protocol W (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2778074) Post-Hoc Analysis of CLARITY (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2777497?resultClick=1) Racial and Socioeconomic Differences in DME Treatment (https://www.aaojournal.org/article/S0161-6420(21)00196-2/abstract) Anti-VEGF for Wet AMD Prophylaxis (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2777577?resultClick=1)

The phase 3 TENAYA and LUCERNE trials, which assessed the safety and efficacy of faricimab for wet AMD therapy, have wrapped up. What did the researchers learn? New Retina Radio spoke with Arshad Khanani, MD, MA, about his ARVO presentation on these trials. We also spoke with David Lally, MD, whose ARVO presentation adds new data to the great fluid debates in wet AMD. What did his research team uncover that can inform our understanding of fluid dynamics in these patients?  

In this episode with speak with David Ramsey, an Ophthalmologist from the Lahey Hospital & Medical Center, Beth Israel Lahey Health, in Massachusetts, USA. We speak about his recent paper, 'Underdiagnosis of glaucoma in patients with exudative age-related macular degeneration’ and discuss whether there is a link between glaucoma and wet-AMD and why that may be. --- Send in a voice message: https://anchor.fm/eyetoeye/message

Outlook Therapeutics, Inc (NASDAQ:OTLK) Lawrence Kenyon updated Proactive on the Monmouth, New Jersey-based biotech group's recent clinical advances. Kenyon says the group, who recently reported a positive safety profile in its NORSE THREE open-label safety study to treat wet AMD, says the group is almost complete with its pivotal Phase 3 NORSE TWO trial, expected to report that data in 3Q of 2021. Later within the year, it will then submit a BLA filing.

A new website and campaign supported by the Macular Society has just launched titled ‘See What's Next' providing information and support for people with wet age related macular degeneration including case studies, hints and tips, life hacks and much more to enable people to manage Wet AMD and maintain an independent life.Connect Radio's Toby Davey chats with Cathy Yelf, Macular Society Chief Executive to find out more about the ‘See What's Next' campaign and why the campaign is so important at the moment during the Covid pandemic.Cathy also explained why it is so important for people with Wet AMD to attend their clinic appointments and what measures have been put in place to ensure that clinic appointments are safe and Covid Secure. The ‘See What's Next' website can be found by visiting the following link - https://www.seewhatsnext.co.uk and do visit the Macular Society website for other helpful information and advice about Macular degeneration -  https://www.macularsociety.org (Image shows RNIB logo. 'RNIB' written in black capital letters over a white background and underlined with a bold pink line, with the words 'See differently' underneath) 

Which upcoming therapies will extend duration for patients with wet AMD? John Kitchens, MD, sits down with Diana Do, MD, and Carl Regillo, MD, to hear about their presentations at this year’s Angiogenesis, Exudation, and Degeneration annual meeting. After the break, Drs. Kitchens, Do, and Regillo discuss how the future of wet AMD therapies may alter clinical care for patients undergoing treatment. 

Dr. Carmen Puliafito interviews Andrew Moshfeghi, MD on a topic: Tyrosine Kinase Inhibitor Delivery by Hydrogel for Treatment of Wet AMD

Peter Kaiser, MD, and Timothy Murray, MD, MBA, discuss the HAWK and HARRIER phase 3 studies evaluating the safety and efficacy of brolucizumab for wet AMD.

Welcome to a new episode of this imaging series on EyePod Bayer. In the previous parts of this series, we talked about the anterior segment, and now we are going to continue with imaging of the back of the eye and retina with OCT and OCT-A , beginning with wet AMD. This is the third part of the interview with Neil and Stamatis, where we talk about OCT-A in clinical practice with focus on wet AMD. In the next interviews, we will talk about OCT and OCT-A in Diabetic Retinopathy, stay tuned!  Enjoy! eyepod@bayer.com   MA-M_AFL-DK-0032-1    

This NRR miniseries "The Art of Drug Choice: Wet AMD and the Latest Data" continues as Dr. Khanani and the roundtable participants Drs. Fuller, London, and Weng review the wet AMD pipeline with a focus on anti-Ang-2 therapy (faricimab, Roche/Genentech) and gene therapy (RGX-314, RegenxBio and ADVM-022, Adverum Biotechnologies). After the break, Dr. London shares the case of a patient with wet AMD who experienced a ceiling of response to anti-VEGF therapy. Did a switch to brolucizumab (Beovu, Novartis) result a change?

In episode 2 of the NRR miniseries "The Art of Drug Choice: Wet AMD and the Latest Data," Dr. Khanani and roundtable participants Drs. Fuller, London, and Weng review the latest phase 3 efficacy data from the HAWK/HARRIER, ARCHWAY, and CEDAR/SEQUOIA studies. Also, Dr. Weng shares the case of a wet AMD patient whose response to therapy and toleration of treatment burden mandated a change in treatment. Could brolucizumab (Beovu, Novartis) be a solution?

NRR's miniseries "The Art of Drug Choice: Wet AMD and the Latest Data" wraps up with moderator Dr. Khanani and panelists Drs. Fuller, London, and Weng discussing safety data. How have safety considerations changed in the wet AMD treatment landscape, and how do clinicians balance the risks and rewards of switching to a new agent? Additionally, Dr. Khanani closes out the series with the case of a patient whose disease stopped responding after a decade of anti-VEGF therapy. Listen here to learn how he approached the case.

NRR’s miniseries “The Art of Drug Choice: Wet AMD and the Latest Data” wraps up with moderator Dr. Khanani and panelists Drs. Fuller, London, and Weng discussing safety data. How have safety considerations changed in the wet AMD treatment landscape, and how do clinicians balance the risks and rewards of switching to a new agent? Additionally, Dr. Khanani closes out the series with the case of a patient whose disease stopped responding after a decade of anti-VEGF therapy. Listen here to learn how he approached the case. 

This NRR miniseries “The Art of Drug Choice: Wet AMD and the Latest Data” continues as Dr. Khanani and the roundtable participants Drs. Fuller, London, and Weng review the wet AMD pipeline with a focus on anti-Ang-2 therapy (faricimab, Roche/Genentech) and gene therapy (RGX-314, RegenxBio and ADVM-022, Adverum Biotechnologies). After the break, Dr. London shares the case of a patient with wet AMD who experienced a ceiling of response to anti-VEGF therapy. Did a switch to brolucizumab (Beovu, Novartis) result a change? 

In episode 2 of the NRR miniseries “The Art of Drug Choice: Wet AMD and the Latest Data,” Dr. Khanani and roundtable participants Drs. Fuller, London, and Weng review the latest phase 3 efficacy data from the HAWK/HARRIER, ARCHWAY, and CEDAR/SEQUOIA studies. Also, Dr. Weng shares the case of a wet AMD patient whose response to therapy and toleration of treatment burden mandated a change in treatment. Could brolucizumab (Beovu, Novartis) be a solution? 

Arshad M. Khanani, MD, MA, leads a roundtable consisting of Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA, as they discuss the art of drug choice in wet AMD therapy. The panel discusses how and why they switch therapy in challenging wet AMD cases and reviews how the COVID-19 pandemic has factored into their treatment algorithms. Also, Dr. Fuller shares the case of a wet AMD patient whose waning response to traditional therapy required intervention with an intravitreal dexamethasone implant (Ozurdex, Allergan). 

Arshad M. Khanani, MD, MA, leads a roundtable consisting of Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA, as they discuss the art of drug choice in wet AMD therapy. The panel discusses how and why they switch therapy in challenging wet AMD cases and reviews how the COVID-19 pandemic has factored into their treatment algorithms. Also, Dr. Fuller shares the case of a wet AMD patient whose waning response to traditional therapy required intervention with an intravitreal dexamethasone implant (Ozurdex, Allergan).

Drs. Nicolas Farber and Nimesh Patel join for a journal club discussing three recent publications in major ophthalmology journals.IRIS registry Noncomplex Phakic RD Outcomes (https://www.ajo.com/article/S0002-9394(20)30456-6/fulltext)Physician Mask Use and Intravitreal Injections (https://www.ajo.com/article/S0002-9394(20)30438-4/fulltext)Lapses in Wet AMD Treatment (https://pubmed.ncbi.nlm.nih.gov/32658164/)Financial Disclosures: Dr. Sridhar is a consultant for Alcon, Dorc, Oxurion, and Regeneron. Drs. Farber and Patel have no disclosures.You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audio&sub=ONE.ContentTypes.Audio.

Dr. Mali talks about advancements in treatment and screening for Wet AMD.

A chat with my Carer about everyday living with Wet AMD.

You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audio&sub=ONE.ContentTypes.Audio.

Dr. Dugel discusses 1 and 2 year results of HAWK and HARRIER on Brolucizumab for neovascular AMD.  Full reference:  Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., . . . Investigators, H. S. (2019). HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. doi:10.1016/j.ophtha.2019.04.017  

Dr. Mark Gillies from Sydney, Australia discusses 2-year results of the RIVAL Study which investigated rates of geographic atrophy and visual acuity changes in patients with wet AMD.   Full reference:  Gillies, M. C., Hunyor, A. P., Arnold, J. J., Guymer, R. H., Wolf, S., Ng, P., . . . McAllister, I. L. (2019). Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2018.6776  

Dr. Ajay Kuriyan from University of Rochester and Dr. Shriji Patel from Vanderbilt University the show for a journal club focusing on 3 recent publications in major ophthalmology journals, including a prospective study examining ranibizumab and aflibercept for wet macular degeneration, a sub analysis examining factors associated with better anatomic and visual improvements in Protocol T, and paper detailing the natural history of central serous retinopathy. IVR versus IVA for wet AMD (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2722672) Protocol T subanalysis (https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2722673) CSR natural history (https://www.aaojournal.org/article/S0161-6420(17)32067-5/fulltext) Financial Disclosures: Dr. Kuriyan is a consultant for Regeneron, Allergan, Alimera, and Valeant and receives grant funding from Second Sight. Dr. Patel has no disclosures. Dr. Sridhar is a consultant for Allergan, Alimera Science, and Alcon Laboratories.

The telephone discussion features Christopher Brittain, MB, BS, BSc (Hons), MBA, DIC, MRCOphth, who is Interim Global Head of Ophthalmology Clinical Development at Genentech.

REGENXBIO founding CEO Ken Mills reviews the company’s recent positive Phase I results for RGX-314, a potentially game-changing gene therapy for wet AMD. Mills also shares the responsibility he feels leading a pioneer in the blockbuster gene therapy field.

Dr. Sean Adrean discusses his retrospective analysis of patients with wet AMD who had over 50 anti-VEGF injections. Full reference of the discussed article: Adrean, S. D., S. Chaili, H. Ramkumar, A. Pirouz, and S. Grant. "Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-Vegf Injections Using a Treat-Extend-Stop Protocol." Ophthalmology  (Feb 10 2018).

KOLs, CEOs, and analysts say Ophthotech’s disappointing Fovista trials alter the landscape for companies developing new treatments for wet AMD. And all agree, the biggest losers in all of this are patients suffering from the disease.

Dr. Carl Regillo of the Wills Eye Hospital in Philadelphia, PA joins the podcast to discuss treat and extend strategies for wet age-related macular degeneration (AMD), his approach to retinal detachment surgery, and other topics. Also, Dr. Yewlin Chee of the University of Washington joins the podcast in this week's Young VR Surgeon Spotlight.

Graybug interim CEO Jeff Cleland shares details on the company’s $44.5 million Series B. Cleland gives a report on investor appetite for ophthalmology companies. He also explains how the firm would use the capital to shift its approach from a drug delivery platform technology company to a drug maker.

Australia-based Opthea is moving forward with clinical trials in the US, testing its OPT-302 compound along and in combination with Lucentis as a potential treatment for Wet AMD. CEO Megan Baldwin explains the company’s approach up until now and its plans going forward.

This telephone discussion features Michael B. Gorin, MD, PhD, an ophthalmologist from UCLA who is devoted to research and clinical care of hereditary retinal disorders, especially age-related macular degeneration, retinal dystrophies and other medical retinal conditions.

This telephone discussion features Michael B. Gorin, MD, PhD, an ophthalmologist from UCLA who is devoted to research and clinical care of hereditary retinal disorders, especially age-related macular degeneration, retinal dystrophies and other medical retinal conditions.

This telephone discussion features Michael B. Gorin, MD, PhD, an ophthalmologist from UCLA who is devoted to research and clinical care of hereditary retinal disorders, especially age-related macular degeneration, retinal dystrophies and other medical retinal conditions.

Host Neil Bressler, MD, interviews Jennifer Lim, MD, and Judy Kim, MD. Dr. Neil Bressler leads a discussion on the management of patients with age-related macular degeneration. The participants consider a range of issues, including their approach to antibiotic use, the real-world implication of the published CATT outcomes, and the challenge of motivating patients who may be discouraged by a long-term regimen of intravitreal injections. (November 2011)